CD68 and psoriasis: Taken together with clinical indicators in the dynamics of psoriasis treatment with PGZ, such as a decrease of PASI index and reduction of relapse rate up to 1-2 times per year [7, 8, 32], decreasing of CD68+ cells indicates inhibition of inflammation locally.